Non-CF Resources and Support
Through MySampleCloset, practices are able to easily request:

Samples of ZENPEP® at any strength
To learn more, visit MySampleCloset.com.

The ZENPEP Patient Support Program
The ZENPEP Patient Support Program (for patients with EPI due to non-CF conditions) is available for eligible residents of the United States and Puerto Rico. As members, patients can receive:

Discounted out-of-pocket costs—eligible patients may pay as little as $0 for their first ZENPEP prescription fill and as little as $30 for refills*

FREE vitamins and supplements

Refill and dosing reminders

Live support from customer care advocates
To learn more about program registration and savings card activation, visit the ZENPEP Patient Support Program website.
CF=cystic fibrosis; EPI=exocrine pancreatic insufficiency.
*This offer is valid only for ZENPEP prescriptions. Eligible patients may pay as little as $0 per ZENPEP 30-day prescription fill and up to $30 for refills. This offer is valid for up to twelve (12) prescription fills of a 30-day supply. Check with pharmacist for copay discount. Maximum savings limit applies; patient out-of-pocket expense may vary. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see Non-CF Patient Support Program Terms, Conditions, and Eligibility Criteria at www.ZENPEPsupport.com.
More than 9 out of 10 patients are covered for ZENPEP1,2§
-Commercial insurance: 92%; Medicare insurance: 95%
§Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. Nestlé Health Science does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.
References: 1. MMIT Data on File. Nestlé Health Science. Accessed February 1, 2021. 2. MMIT Data on File. Nestlé Health Science. Accessed November 3, 2020.